UCB Pharma - Top 5 layoffs of 2008
Company: UCB Pharma
Layoffs: 2,000
Summary: Citing impending patent expirations, Belgium's UCB Pharma said it would cut 2,000 jobs, or 17 percent of its workforce. Zyrtex went off patent in 2007 and the company's top-selling epileptic treatment, Keppra, will go off patent in 2009,. UCB will dedicate €300 million over the next three years to become a central nervous system and immunology disease company. UCB recently won approvals for Cimzia for Crohn's disease in the U.S. and the positive opinions for Neupro for RLS and Vimpat for epilepsy in Europe.
The drug developer said about 2,400 positions will become redundant, but that it will be creating around 400 new jobs. Three hundred other positions will be re-deployed to UCB's core sites.
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: